Current stock page

Financial Data

NVAX Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

NVAXNovavax, Inc.

Healthcare / Biotechnology

$8.53−$0.23 (−2.68%)

Latest quote

  • Momentum
    77
  • Value
    —
  • Quality
    62
  • Risk resilience
    38
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$68.3M$56.7M$139.51M$147.14M$70.45M$239.24M$666.66M$88.31M
Gross Profit$44.81M$42.45M$108.82M$121.94M$48.95M$225.02M$652.54M$51.64M
Operating Income-$31.28M-$54.91M-$15.43M$21.02M-$178.02M$105.67M$515.51M-$131.08M
Net Income-$31.38M-$53.39M-$9.49M$17.53M-$202.38M$106.51M$518.65M-$81.03M
EPS-$0.19-$0.32-$0.06$0.11-$1.25$0.66$3.22-$0.51
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$94.24M-$75.41M-$32.42M-$39.48M$107.8M-$127.46M-$185.5M-$173.16M
Capital Expenditure-$1.02M-$588K-$1.27M-$2.08M-$2.02M-$247K-$1.6M-$2.25M
Free Cash Flow-$95.26M-$75.99M-$33.69M-$41.55M$105.79M-$127.71M-$187.1M-$175.42M
Net Cash Provided By Operating Activities-$94.24M-$75.41M-$32.42M-$39.48M$107.8M-$127.46M-$185.5M-$173.16M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$888.01M$955.58M$1.04B$1.18B$1.18B$1.34B$1.29B$1.56B
Total Debt$295.26M$295.6M$295.06M$248.81M$251.14M$228.49M$228.66M$230.42M
Cash And Cash Equivalents$222.46M$191.46M$228.36M$240.63M$268.02M$253.74M$263.34M$530.23M
Total Liabilities$1.1B$1.15B$1.19B$1.3B$1.34B$1.3B$1.37B$2.18B
Total Stockholders Equity-$216.86M-$190.71M-$144.76M-$127.75M-$156.67M$37.63M-$75.64M-$623.84M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio———4.43.613.182.47—
P/B ratio—————35.7——
P/S ratio3.42———————
Debt To Equity—————6.07——
Free Cash Flow Yield-13.76%-3.42%-6.36%-12.94%-31.20%-47.42%-16.75%-9.01%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio———4.43.613.182.47—
P/B ratio—————35.7——
P/S ratio3.42———————
Return On Equity—————11.24%——
Debt To Equity—————6.07——

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-18.53x
Pb-6.48x
Revenue Growth Yoy-3.05%
EPS Growth Yoy84.80%
Gross Margin77.25%
Operating Margin-19.58%
ROE45.13%
ROIC-14.40%
Debt To Equity-1.36
FCF Yield-17.52%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$8.53
Volume4.64M
RSI (14)37.64
MACD-0.37
MACD signal-0.2
MACD histogram-0.17
ADX (14)24.04
SMA (50)$10.54
SMA (200)$9.33
ATR (14)$0.86
Historical volatility (annualized)97.06%
Volume (20-day average)6.23M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score38/100
Beta2.12
Annual volatility73.62%
Max Drawdown-34.58%
Sharpe Ratio0.56
VaR (95%, 1-day)-6.08%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

NVAX Financial Data FAQ

What is Novavax, Inc.'s revenue?

Novavax, Inc.'s revenue is one of the core financial data points for NVAX. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Novavax, Inc.'s revenue growing?

Revenue growth shows whether Novavax, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is NVAX's EPS?

NVAX's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Novavax, Inc.'s net income?

Novavax, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Novavax, Inc. generate?

Free cash flow shows how much cash Novavax, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Novavax, Inc. have?

Cash and debt help frame NVAX's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.